Drugs / Cortisone-d8
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05409027 Background | Jul 2021 → Mar 2022 | obesity disorder, type 2 diabetes mellitus | Sparrow Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cortisone-d8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05409027 ↗ |
| Route | Subcutaneous | “Each subject will receive up to 12 mcg cortisone-d8 SC during each of one or more study visits.” NCT05409027 ↗ |